
    
      The objective of this trial is to evaluate the safety and dose tolerability of VT-122 regimen
      and to evaluate the efficacy of VT-122 regimen

      This trial is to be conducted on patients who have a diagnosis of Stage IV NSCLC, are not on
      chemotherapy, have lost 5% of their body weight in the previous 2 months and are deemed to be
      hypercatabolic.
    
  